Prescription Drug Pricing in America – a 3-Part Update, From the Over- the-Counter OPill and “Half-Price” Ozempic to Most-Favored-Nation Rx (Part 3)
Welcome to Part 2 of 3 in my consideration of Prescription Drug Pricing in America. You can catch up with yesterday’s Part 1 post here, and Part 2 here. The macro-context for these 3 posts are the forecasts for health care spending for the coming year. Health care cost increases forecasted for 2026 will, in significant part, be driven by prescription drug trend. This graphic from this week’s release of the Business Group on Health’s employer survey on healthcare cost growth to 2026 illustrates a key finding that’s echoed in other similar studies recently released and covered here in Health Populi.
Prescription Drug Pricing in America – a 3-Part Update, From the Over- the-Counter OPill and “Half-Price” Ozempic to Most-Favored-Nation Rx (Part 1)
Health care costs will increase, overall, as much as 10% in 2026, the consensus of several health benefit analysts inform us. And, “workers to bear brunt of health cost increases in 2026,” reads today’s Axios headline on the topic, weaving together several studies from the Business Group on Health, Mercer, and the International Foundation of Employee Benefit Plans. A kay cost-contributor cited in all of these health cost forecasts is the prescription drug line item: specialty drug prices, and specifically the costs of GLP-1 medicines and cancer therapies. One strategy gaining fast-traction on both the
GLP-1s at the Pharmacy – A Lens on Consumer-Driven Retail Health (with Hims & Hers stock price update)
The nature of retail pharmacy is changing, with both threats and opportunities re-shaping the business itself, and the pharmacy’s role in the larger health/care ecosystem. To keep sharp on the topics, I attended Rx Market Insights: Performance Trends and Outlook for 2025, a data-rich session presented on February 18 by IQVIA and sponsored by Ascend Laboratories. The webinar was hosted by DSN (Drug Store News), appropriately so because the action-packed hour went into detail providing the current state of prescription drugs and the pharmacy in America. Doug Long, IQVIA’s VP of Industry Relations, and Scott Biggs, the company’s Director of Supplier
I'm once again pretty gobsmackingly happy to have been named a judge for the 2026 CES Innovation Awards, focusing on digital health, longevity, and fitness. Preceding every year's global conference, CES receives hundreds of applications from innovators around the world building tech-based solutions to big challenges. So glad to be part of this annual initiative to see what global health-tech pioneers are cooking up to address and scale the health and well-being of fellow health citizens, globally.
You can see the results of the Digital Health Awardees here on the #CES2026 website.
Stay tuned to Health Populi in early January as I'll be attending Media Days and meeting with innovators in digital health, longevity, and the home-for-health during CES 2026 in Las Vegas. I'll be at the conference for an entire week meeting with clients and exhibitors at the biggest-meeting-of-the-year on consumer-facing technology. I'll be reporting daily from Vegas here in the blog, sharing with you insights about the latest breakthroughs, products, and services that enable people to manage health, well-being, and medical issues in their own hands and homes.
Jane collaborated on Robin Strongin's Health Dame webcast to discuss Halle Tecco's new book, Massively Better Healthcare, due out in early 2026. We brainstormed with Maven Founder Kate Ryder and the company's Chief Medical Officer Dr. Neel Shah about the state of U.S. healthcare and solutions not just to tweak at the margins but to "massively" improve health care delivery, financing, outcomes, and equity in America. It was a delightful, enlightening conversation -- I hope you'll check it out.